Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cellvation Tackling Traumatic Brain Injuries With Stem Cell Therapy

Executive Summary

Emerging Company Profile: With mononuclear stem cell therapy from University of Texas research, new company hopes to address traumatic brain injury by reducing the pro-inflammatory cytokine cascade, which exacerbates the initial injuries in severe TBI.

You may also be interested in...



Fortress Adds New Rare Disease-Focused Subsidiary

Cyprium joins Fortress’ growing company portfolio, which now includes nine subsidiaries focused on a broad range of disease. Fortress CEO Rosenwald aims to add one to two new companies a quarter under the Fortress umbrella.

Tech Transfer Roundup: Entrepreneurial Culture Matters

Believing biomedical research at Duke is “under fished” compared to the ponds in San Francisco and Boston, Duke’s institutional CRO looks to provide clinical trial design and other services to help tech transfer along. Plus, recent tech transfer deals include AbbVie, Calimmune and China’s Yisheng.

Fujifilm Promises A Shake-Up Of Regenerative Medicines Market

Fujifilm has successfully transformed its business strategy by expanding away from traditional photographic film and toward new priority business fields – significantly in regenerative medicine. Identifying health care as a key growth area, Fujifilm targets the role of being a comprehensive provider in the fields of prevention, diagnosis and treatment.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC097624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel